domingo, 1 de febrero de 2026
RFK Jr. Makes False Claims about Covid Deaths, Vaccine Safety at Senate Hearing
https://climate.law.columbia.edu/content/rfk-jr-makes-false-claims-about-covid-deaths-vaccine-safety-senate-hearing?utm_campaign=KHN%20-%20Weekly%20Edition&utm_medium=email&_hsenc=p2ANqtz--9W5XadfyOU4FAB4WPJSGME5Zyorfigptqxkx7GYGTRnixCtjQe3M9leBzeOmDpqEruWaGVjBXCNemxuff35T94UG-7A&_hsmi=401263459&utm_content=401263459&utm_source=hs_email
On September 4, 2025, Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., made several false or misleading statements during a Senate Finance Committee hearing, including claiming that “there’s no clinical data” to support Covid vaccine recommendations for healthy people and that “nobody knows” how many Americans have died from Covid.
A Closer Look at Nebraska, the First State Planning to Implement a Medicaid Work Requirement Authors: Amaya Diana and Anna Mudumala Published: Jan 30, 2026
https://www.kff.org/medicaid/a-closer-look-at-nebraska-the-first-state-planning-to-implement-a-medicaid-work-requirement/
In December, Nebraska was the first state to announce that it would be enforcing Medicaid work requirements early, starting May 1, 2026. The 2025 reconciliation law requires states to condition Medicaid eligibility for adults in the ACA Medicaid expansion group and enrollees in partial expansion waiver programs (Georgia and Wisconsin) on meeting work requirements starting January 1, 2027; however, states have the option to implement requirements sooner through a state plan amendment or through an approved 1115 waiver. Implementing work requirements will require complex changes to eligibility and enrollment...
Recent Trends in GLP-1 Use and Spending in Medicare Author: Juliette Cubanski Published: Jan 30, 2026
https://www.kff.org/medicare/recent-trends-in-glp-1-use-and-spending-in-medicare/
Ahead of the Trump administration’s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicare’s negotiated price for certain GLP-1 products beginning in 2027, new data from the Centers for Medicare & Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions. Medicare currently covers GLP-1s for type 2 diabetes, cardiovascular disease, and sleep apnea, but coverage for weight loss drugs is prohibited by law, even as GLP-1s have proved to be highly effective for this purpose (and even cost-effective, according to a recent analysis).
Suscribirse a:
Entradas (Atom)
